John Overdeck’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $99.2M | Buy |
1,642,848
+1,036,763
| +171% | +$57.6M | 0.07% | 309 |
|
|
2026
Q1 | $35.2M | Buy |
606,085
+169,342
| +39% | +$7.8M | 0.03% | 652 |
|
|
2025
Q4 | $19.6M | Buy |
+436,743
| New | +$18.3M | 0.03% | 735 |
|
|
2025
Q2 | – | Sell |
-236,983
| Closed | -$7.95M | – | 3585 |
|
|
2025
Q1 | $7.95M | Sell |
236,983
-36,369
| -13% | -$1.38M | 0.02% | 864 |
|
|
2024
Q4 | $10.7M | Buy |
273,352
+29,773
| +12% | +$1.23M | 0.02% | 725 |
|
|
2024
Q3 | $9.6M | Buy |
243,579
+48,450
| +25% | +$1.95M | 0.02% | 777 |
|
|
2024
Q2 | $7.61M | Sell |
195,129
-79,497
| -29% | -$3.18M | 0.02% | 819 |
|
|
2024
Q1 | $11.8M | Sell |
274,626
-65,389
| -19% | -$3.01M | 0.03% | 600 |
|
|
2023
Q4 | $15.7M | Buy |
340,015
+259,382
| +322% | +$9.16M | 0.04% | 497 |
|
|
2023
Q3 | $2.75M | Buy |
80,633
+62,000
| +333% | +$2.32M | 0.01% | 1207 |
|
|
2023
Q2 | $717K | Buy |
18,633
+7,179
| +63% | +$285K | ﹤0.01% | 2147 |
|
|
2023
Q1 | $410K | Buy |
+11,454
| New | +$423K | ﹤0.01% | 2291 |
|
|
2022
Q4 | – | Sell |
-55,974
| Closed | -$2.02M | – | 3112 |
|
|
2022
Q3 | $2.02M | Buy |
+55,974
| New | +$2.01M | 0.01% | 1144 |
|
|
2022
Q2 | – | Sell |
-232,650
| Closed | -$7.11M | – | 2984 |
|
|
2022
Q1 | $7.11M | Sell |
232,650
-45,693
| -16% | -$1.37M | 0.02% | 758 |
|
|
2021
Q4 | $8.7M | Buy |
278,343
+108,667
| +64% | +$3.25M | 0.02% | 875 |
|
|
2021
Q3 | $2.59M | Buy |
169,676
+84,458
| +99% | +$1.47M | 0.01% | 1736 |
|
|
2021
Q2 | $1.59M | Buy |
85,218
+8,512
| +11% | +$157K | ﹤0.01% | 2082 |
|
|
2021
Q1 | $1.37M | Buy |
76,706
+26,145
| +52% | +$443K | ﹤0.01% | 2028 |
|
|
2020
Q4 | $778K | Buy |
50,561
+576
| +1% | +$6.74K | ﹤0.01% | 2193 |
|
|
2020
Q3 | $553K | Sell |
49,985
-70,130
| -58% | -$825K | ﹤0.01% | 2166 |
|
|
2020
Q2 | $1.51M | Buy |
120,115
+31,510
| +36% | +$401K | 0.01% | 1255 |
|
|
2020
Q1 | $1M | Buy |
88,605
+11,788
| +15% | +$168K | 0.01% | 1410 |
|
|
2019
Q4 | $1.01M | Buy |
+76,817
| New | +$808K | ﹤0.01% | 2179 |
|
|
2019
Q2 | – | Sell |
-58,149
| Closed | -$591K | – | 3715 |
|
|
2019
Q1 | $591K | Sell |
58,149
-142,112
| -71% | -$1.2M | ﹤0.01% | 2167 |
|
|
2018
Q4 | $1.26M | Buy |
200,261
+123,676
| +161% | +$1.1M | ﹤0.01% | 1494 |
|
|
2018
Q3 | $1.01M | Buy |
+76,585
| New | +$887K | ﹤0.01% | 1976 |
|
Other funds holding XENE
John Overdeck's XENE Position: Q2 2026 in Review
John Overdeck increased its Xenon Pharmaceuticals (XENE) stake by 171% in Q2 2026, buying an estimated $57.6M and bringing the position to 1,642,848 shares worth $99.2M. The position accounts for 0.07% of the portfolio, ranked #309.
John Overdeck first reported a position in XENE in Q3 2018 and has held it in 26 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.
- John Overdeck held 1,642,848 shares of Xenon Pharmaceuticals worth $99.2M as of Q2 2026.
- John Overdeck bought 1,036,763 Xenon Pharmaceuticals shares in Q2 2026, an estimated $57.6M.
- Xenon Pharmaceuticals made up 0.07% of John Overdeck's portfolio in Q2 2026, its #309 holding.
- John Overdeck first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
- 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.